The role of PARP inhibitor combination therapy in ovarian cancer

The use of PARP inhibitors (PARPi) has transformed the care of advanced high-grade serous/endometrioid ovarian cancer. PARPi are now available to patients in both the first-line and recurrent platinum-sensitive disease settings; therefore, most patients will receive PARPi at some point in their trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hockings, Helen, Miller, Rowan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196552/
https://www.ncbi.nlm.nih.gov/pubmed/37215065
http://dx.doi.org/10.1177/17588359231173183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196552/
https://www.ncbi.nlm.nih.gov/pubmed/37215065
http://dx.doi.org/10.1177/17588359231173183

Ejemplares similares